GHRS
GH Research PLC
Company Overview
| Mkt Cap | $1.50B | Price | $22.96 |
| Volume | 204.74K | Change | +3.77% |
| P/E Ratio | -31.2 | Open | $22.37 |
| Revenue | -- | Prev Close | $22.12 |
| Net Income | $-48.3M | 52W Range | $10.96 - $24.66 |
| Div Yield | N/A | Target | $39.50 |
| Overall | 61 | Value | 60 |
| Quality | 34 | Technical | 90 |
No chart data available
About GH Research PLC
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Latest News
Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA), GH Research (GHRS) and Doximity (DOCS)
Analysts Are Bullish on Top Healthcare Stocks: GH Research (GHRS), MapLight Therapeutics, Inc. (MPLT)
GH Research Launches $200 Million At-the-Market Share Offering With Stifel
Wall Street Analysts Are Bullish on Top Healthcare Picks
GH Research Posts Wider Q1 2026 Loss as R&D and Admin Costs Rise
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GHRS | $22.96 | +3.8% | 204.74K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |